Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
PSMA-Targeted Radioligand Therapy

Lutetium-177 PSMA-617

Brand names: Pluvicto

Lutetium-177 PSMA-617 is a radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer that has progressed after other treatments.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

The ligand binds prostate-specific membrane antigen on prostate cancer cells, delivering targeted beta-emitting lutetium-177 radiation that damages tumour-cell DNA.

Prescribing in practice

  • As an unsealed radioactive product it requires administration under nuclear-medicine governance with strict radiation-protection precautions for patients, carers and staff.
  • Myelosuppression, including thrombocytopenia and anaemia, can occur and requires haematological assessment before and during treatment.
  • Renal impairment, dry mouth and gastrointestinal effects may occur; eligibility depends on PSMA-positive imaging and adequate organ function per the SPC.

Monitoring

Monitor full blood count, renal and liver function and PSA response, with PSMA imaging used to confirm eligibility before treatment.

Counselling the patient

  • You will need to follow radiation-safety advice for a period after each dose, including distance from others and hygiene measures.
  • Drink fluids as advised to help protect the kidneys and salivary glands.
  • Report unusual bruising, bleeding, breathlessness or signs of infection.

Evidence & guidelines

The VISION trial supported lutetium-177 PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer after prior therapy.

Reference: VISION trial (Sartor et al. NEJM 2021); NICE TA878; MHRA SPC Pluvicto 2022; EAU Prostate Cancer Guidelines 2024; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways